Abstract
On the basis of the discussions at a symposium held in Düsseldorf and attended by respresentatives of various interested bodies, European legislation as it affects radiopharmaceuticals is reviewed. Due consideration is given to the new, centralised and decentralised, registration procedures, effective since 1 January 1995. The dossier required to support an application for marketing authorisation is discussed, separate consideration being given to single-photon emitters, therapeutic radionuclides and positron-emitting radiopharmaceuticals. The role of the European Pharmacopoiea is also considered. It is concluded that the new, modified procedures for the registration of medicinal products in the European Union may actually inhibit free availability of radiopharmaceuticals within the Community, and that there is a strong case for modification of the European Directives so that radiopharmaceuticals are placed in a separate category to therapeutic drugs, with less stringent registration requirements.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hewat CDR, Ogle J, Fallais C. Radiopharmaceuticals and the single European Market.Eur J Nucl Med 1993; 20:657–660.
Cox PH. European legislation affecting radiopharmaceuticals: cold fusion or illusion? J Nucl Biol Med 1994; 38:518–520.
Cartwright AC. Harmonisation of European requirements for quality of medicinal products: countdown to 1992.Pharm Tech Int April 1990:32–37.
Product liability and the pharmacist.Pharm J 1986; 237:744–745.
Guide to good pharmaceutical manufacturing practice. London: HMSO Books. ISBN 0 11 320832 4.
Guide to good manufacturing practice. In:Netherlands pharmacopoeia, 9th edn, incorporating the European Pharmacopoeia, 2nd edn [in English] 519–559. (Also available in all National versions of the Ph Eur).
EMEA and the EC regulatory future.Pharm J 1994; 253:68–69.
Cox PH. Radiopharmaceuticals toxicity and safety. In: Deckart H, Cox PH, eds.Principles of radiopharmacology. Jena: Gustav Fischer; 1987:240–245.
Shapiro B, Pillay M, Cox PH. Dosimetric consequences of interstitial extravasation following IV administration of a radiopharmaceutical.Eur J Nucl Med 1987; 12:552–553.
Tubiana M. Risks associated with the use of radiopharmaceuticals. In: Raynaud C, ed.Nuclear medicine and biology IV. Oxford: Pergamon Press; 1982:2603.
Cox PH. Criteria for the use of monoclonal antibodies, legislation and ethical considerations.Nucl Med Comm 1993; 14:653–657.
Guide to inspections of liquid injectable radiopharmaceuticals used for positron emission tomography. Washington: Food and Drugs Administration, November 1993.
Kilbourne MR, et al. Quality assurance of short-life radiopharmaceuticals. In: Warbick-Cerone A, Johnston LG, eds.Quality assurance of pharmaceuticals manufactured in the hospital. Oxford: Pergamon Press; 1984.
Vera Ruiz H.Report of the IAEA Expert Advisory Meeting on the quality control of cyclotron produced radiopharmaceuticals. Heidelberg. Vienna: IAEA, 1988.
Vera Ruiz H.Quality control of cyclotron produced radiopharmaceuticals. Vienna: IAEA, 1989.
Cox PH, et al. Report and recommendations on the requirements for post-graduate training in radiopharmacy and radio pharmaceutical chemistry 1989.Eur J Nucl Med 1990; 17:203–211.
Cox PH. EEC directives and guidelines applicable to radiopharmaceuticals — 1993.Eur J Nucl Med 1993; 20:712–715.
Ell PJ. Challenges for nuclear medicine in the 1990's.Nucl Med Commun 1992; 13:65–75.
Author information
Authors and Affiliations
Consortia
Rights and permissions
About this article
Cite this article
Cox, P.H., Meyer, G.J. & European association of nuclear medicine committees on radiopharmaceuticals and positron emission tomography. Radiopharmaceuticals 1994. Eur J Nucl Med 22, 563–570 (1995). https://doi.org/10.1007/BF00817284
Issue Date:
DOI: https://doi.org/10.1007/BF00817284